#United States #San Diego #Rakuten Medical #Alluminox #Minami Maeda

Rakuten Medical Undergoes Executive Leadership Shift

In a significant development in the world of biotechnology, Rakuten Medical, Inc. has announced a leadership transition aimed at strengthening its operational execution and enhancing organizational discipline. The company has appointed Minami Maeda, the current President, as the new Chief Executive Officer (CEO) effective July 1, 2026. This strategic move positions the company as it prepares for its next growth phase, emphasizing its commitment to its mission of 'Conquering Cancer'.

Former CEO Hiroshi 'Mickey' Mikitani will assume the role of Executive Chairman of the Board, continuing to guide the company’s strategic direction. This transition reflects an evolution in leadership that is expected to drive agility and focus within Rakuten Medical as it strives to make strides in the biotech landscape.

Accelerating Progress Towards U.S. Commercial Launch

The change in leadership comes at a crucial time as Rakuten Medical gears up to launch its flagship Alluminox® platform-based photoimmunotherapy in the U.S. market. With aspirations to accelerate their Phase 3 clinical trial for the treatment of recurrent head and neck cancer, the company aims to submit a Biologics License Application (BLA) to the U.S. FDA by 2028. This trial, designated as ASP-1929-381, evaluates the effectiveness of ASP-1929 in combination with pembrolizumab as a primary treatment modality.

The company is already ahead regarding patient enrollment across multiple regions, including the United States, Taiwan, Japan, and Ukraine. By intensifying these efforts, Rakuten Medical is preparing for regulatory approvals while simultaneously expanding its therapeutic reach beyond head and neck cancer, exploring various tumor types with support from external grants.

Commitment to Cancer Treatment Innovations

Mikitani expressed his pride in overseeing the development of Rakuten Medical's innovative treatments, noting his personal connection to cancer care through his father’s experience. He has pledged to continue supporting these innovative therapies as Executive Chairman. Maeda, in his new capacity, highlighted the significant progress achieved in clinical development and commercial endeavors within Japan, expressing commitment to further enhance the execution of priorities critical to the company’s objectives.

The Alluminox platform is distinctive as it integrates pharmaceuticals, medical devices, and technologies to create a targeted therapy. It operates through a two-step process involving drug administration followed by targeted illumination. This methodology employs a drug targeting a cancer cell, followed by activation through specific light wavelengths, resulting in localized cell necrosis. It is based on the pioneering work of Dr. Hisataka Kobayashi at the National Cancer Institute.

Looking Toward the Future

As Rakuten Medical transitions into this new phase, the emphasis remains on expanding its global reach and developing innovative treatment options that can provide hope for patients battling various types of cancers. With a renewed commitment to enhancing operational efficacy and strategic execution, all eyes will be on the company as it approaches these critical regulatory milestones.

With both Mikitani and Maeda at the helm, Rakuten Medical is poised to navigate the complexities of the biopharmaceutical landscape, delivering on its promise to innovate and conquer cancer worldwide.

For more insights and updates from Rakuten Medical, please visit their official website.

• ---